Search Results

• • 13 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Inside the 2015 ASCO Genitourinary Cancers Symposium

  Authors:Matteo Santoni, Francesco Massari, Roberto Iacovelli, Chiara Ciccarese, Elena Verri, Luciano Burattini, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20152,275 words Report 1500LAuthor(s): Matteo Santoni [*] aff1 , Francesco Massari aff2 , Roberto Iacovelli aff3 , Chiara Ciccarese aff2 , Elena Verri aff3 , Luciano Burattini aff1 , Rodolfo Montironi aff4 , Franco Nolè aff3 , Giampaolo Tortora...

• KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma

  Authors:Alessandro Bittoni, Francesco Piva, Matteo Santoni, Kalliopi Andrikou, Alessandro Conti, Cristian Loretelli, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20157,250 words Report 1630LAuthor(s): Alessandro Bittoni aff1 , Francesco Piva aff2 , Matteo Santoni aff1 , Kalliopi Andrikou aff1 , Alessandro Conti aff1 , Cristian Loretelli aff1 , Alessandra Mandolesi aff3 , Andrea Lanese aff1 , Chiara Pellei...

• The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

  Authors:Petra Langerbeins, Jasmin Bahlo, Christina Rhein, Paula Cramer, Natali Pflug, Kirsten Fischer, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20154,594 words Report 1590LAuthor(s): Petra Langerbeins [*] aff1 , Jasmin Bahlo aff1 , Christina Rhein aff1 , Paula Cramer aff1 , Natali Pflug aff1 , Kirsten Fischer aff1 , Stephan Stilgenbauer aff2 , Karl Anton Kreuzer aff1 , Clemens-Martin...

• KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

  Authors:Peter Camaj, Stefano Primo, Yan Wang, Volker Heinemann, Yue Zhao, Ruediger Paul Laubender, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20154,297 words Report 1590LAuthor(s): Peter Camaj [*] aff1 aff2 aff3 , Stefano Primo aff1 , Yan Wang aff1 aff3 , Volker Heinemann aff2 aff4 , Yue Zhao aff1 aff3 , Ruediger Paul Laubender aff2 aff5 , Sebastian Stintzing aff2 aff4 , Clemens...

• Circulating tumor cells as biomarkers of head and neck squamous cell carcinoma: an updated view

  Authors:Alberto Mangano, Alessandro Mangano, Georgios D Lianos, Luca Levrini, Monica Picone, Luigi Boni, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20152,234 words Report 1750LAuthor(s): Alberto Mangano [*] aff1 aff2 , Alessandro Mangano aff1 aff3 , Georgios D Lianos aff4 , Luca Levrini aff3 , Monica Picone aff5 , Luigi Boni aff1 aff2 , Gianlorenzo Dionigi aff1 aff2 KEYWORDS circulating...

• Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia?

  Author:Peter D ColeFrom:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20152,180 words Report 1800LAuthor(s): Peter D Cole [*] aff1 aff2 KEYWORDS acute lymphoblastic leukemia; methotrexate; neurocognitive function; oxidative stress; pharmacogenomics Most children treated for acute lymphoblastic leukemia...

• Denosumab for the treatment of giant cell tumor of the bone

  Authors:Thomas Brodowicz, Margit Hemetsberger, and Reinhard WindhagerFrom:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20158,949 words Report 1740LAuthor(s): Thomas Brodowicz [*] aff1 , Margit Hemetsberger aff2 , Reinhard Windhager aff3 KEYWORDS bone turnover; denosumab; GCTB; giant cell tumor of bone; osteoclast activity; osteoclastic giant cells; RANK;...

• Sorafenib: 10 years after the first pivotal trial

  Authors:Gennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, Emanuela Ferraro, Antonio Mazzocca, Ferruccio De Rose, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 201513,754 words Report 1750LAuthor(s): Gennaro Gadaleta-Caldarola aff1 , Stefania Infusino aff2 , Rosa Divella aff3 , Emanuela Ferraro aff4 , Antonio Mazzocca aff5 , Ferruccio De Rose aff6 , Gianfranco Filippelli aff2 , Ines Abbate aff3 , Mario...

• Nanotechnology in the war against cancer: new arms against an old enemy - a clinical view

  Authors:Sten Friberg and Andreas M NystromFrom:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 201510,172 words Report 1600LAuthor(s): Sten Friberg aff1 , Andreas M Nyström [*] aff2 KEYWORDS cancer; clinical oncology; nanomedicine; nanoparticles; therapy Introduction & historical background The scientific giant and prolific...

• US FDA oncology drug approvals in 2014

  Authors:Juliet E Wolford and Krishnansu S TewariFrom:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20158,085 words Report 1560LAuthor(s): Juliet E Wolford aff1 , Krishnansu S Tewari [*] aff1 KEYWORDS accelerated approval; cancer drugs; orphan drug designation; priority review; US FDA; regulatory approval Although heart disease...

• Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review

  Authors:Sara Pusceddu, Filippo De Braud, Fabrizio Festinese, Cristina Bregant, Alice Lorenzoni, Marco Maccauro, et al.From:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20158,367 words Report 1670LAuthor(s): Sara Pusceddu [*] aff1 , Filippo De Braud aff1 , Fabrizio Festinese aff2 , Cristina Bregant aff1 , Alice Lorenzoni aff3 , Marco Maccauro aff3 , Massimo Milione aff4 , Laura Concas aff1 , Barbara Formisano...

• Next-generation surveillance strategies for patients with lymphoma.

  Authors:Jonathon B Cohen, David M Kurtz, Ashley D Staton, and Christopher R FlowersFrom:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 201511,974 words Report 2100LABSTRACT While remission and cure rates for Hodgkin and non-Hodgkin lymphoma continue to improve, surveillance approaches remain controversial, especially in light of recent reports suggesting limited benefit for...

• Applying knowledge of autism to brain cancer management: what do we know?

  Authors:Hari Prasad and Rajini RaoFrom:Future Oncology (Vol. 11, Issue 13) Peer-Reviewed

  July 20152,064 words Report 1900LAuthor(s): Hari Prasad aff1 , Rajini Rao [*] aff1 KEYWORDS chemoradioresistance; EGFR; endosomes; pH regulation; SLC9A9 ; temozolomide "To raise new questions, new possibilities, to regard old problems from a...